サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：過活動膀胱治療の世界市場：産業分析、規模、シェア、成長、動向、予測（2024～2032年）
市場調査レポート
商品コード
1408982

過活動膀胱治療の世界市場：産業分析、規模、シェア、成長、動向、予測（2024～2032年）

Global Overactive Bladder Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日: | 発行: Value Market Research | ページ情報: 英文 248 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
過活動膀胱治療の世界市場：産業分析、規模、シェア、成長、動向、予測（2024～2032年）
出版日: 2024年01月01日
発行: Value Market Research
ページ情報: 英文 248 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の過活動膀胱治療の市場規模は、2022年に43億3,000万米ドルに達し、2023～2030年の予測期間中にCAGR 5.29%で成長し、2030年には約65億4,000万米ドルに達すると予測されています。

過活動膀胱（OAB）治療には、この症状に関連する症状を管理するための様々なアプローチが含まれます。OABは、膀胱壁の筋肉の突然の不随意収縮を特徴とし、頻繁かつ緊急な尿意を引き起こします。治療は、症状を緩和し、個人の生活の質を向上させることを目的としています。

市場力学

過活動膀胱（OAB）治療市場は、いくつかの主要要因によって牽引されています。主な要因としては、特に高齢化社会におけるOABの有病率の増加が挙げられ、効果的な治療オプションに対する需要の高まりにつながっています。医学研究と製薬技術革新の進歩が重要な役割を果たしており、有効性の向上と副作用の軽減を提供する標的薬の開発が進んでいます。市場はさらに、行動療法や生活習慣の改善がOABの効果的な第一選択治療法として認知されつつあることによって形成されています。このような非侵襲的アプローチへのシフトは、行動療法プログラムおよび関連介入市場の拡大に寄与しています。また、他の治療に抵抗性のあるOAB症例に対する神経調節療法や外科的介入も、装置や手技の技術的進歩によって市場に影響を与えています。

この調査レポートは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析を対象としています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは過活動膀胱治療の世界市場における各セグメントを包括的に評価することもできます。過活動膀胱治療産業の成長と動向は、この調査に全体的なアプローチを提供します。

地域分析

本セクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカにおける過活動膀胱治療市場の現在および将来の需要を強調する地域展望をカバーします。さらに、著名な全地域における個々の用途セグメントの需要・推定・予測にも焦点を当てています。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場ハイライト
  • 世界市場スナップショット

第3章 過活動膀胱治療 - 産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場魅力度分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 過活動膀胱治療の世界市場分析：タイプ別

  • 概要：タイプ別
  • 実績データと予測データ
  • 分析：タイプ別
  • 抗コリン薬
  • ミラベグロン
  • ボトックス
  • 神経調節
  • その他

第6章 過活動膀胱治療の世界市場分析：疾患タイプ別

  • 概要：疾患タイプ別
  • 実績データと予測データ
  • 分析：疾患タイプ別
  • 特発性過活動膀胱
  • 神経因性過活動膀胱

第7章 過活動膀胱治療の世界市場分析：流通チャネル別

  • 概要：流通チャネル別
  • 実績データと予測データ
  • 分析：流通チャネル別
  • 病院薬局
  • 小売薬局
  • その他

第8章 過活動膀胱治療の世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他の欧州
  • アジア太平洋売上分析
    • 概要、実績と予測
    • アジア太平洋：セグメント別
    • アジア太平洋：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他のアジア太平洋
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他のラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他の中東・アフリカ

第9章 過活動膀胱治療企業の競合情勢

  • 過活動膀胱治療市場の競合
  • 提携/協力/合意
  • 合併・買収
  • 新製品の発売
  • その他の開発

第10章 企業プロファイル

  • 企業シェア分析
  • 市場集中度
  • Pfizer Inc.
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Medtronic
  • Sumitomo Pharma America Inc.（Urovant Sciences.）
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Hisamitsu Pharmaceutical Co. Inc
  • Macleods Pharmaceuticals Ltd.
  • Endo International plc
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Type (USD MN)
  • Anticholinergics Market Sales by Geography (USD MN)
  • Mirabegron Market Sales by Geography (USD MN)
  • Botox Market Sales by Geography (USD MN)
  • Neuromodulation Market Sales by Geography (USD MN)
  • Other Market Sales by Geography (USD MN)
  • Analysis Market by Disease Type (USD MN)
  • Idiopathic Overactive Bladder Market Sales by Geography (USD MN)
  • Neurogenic Overactive Bladder Market Sales by Geography (USD MN)
  • Analysis by Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales by Geography (USD MN)
  • Retail Pharmacies Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Overactive Bladder Treatment Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Overactive Bladder Treatment Report
  • Market Research Process
  • Market Research Methodology
  • Global Overactive Bladder Treatment Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Type
  • Market Attractiveness Analysis by Disease Type
  • Market Attractiveness Analysis by Distribution Channel
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Type (USD MN)
  • Anticholinergics Market Sales by Geography (USD MN)
  • Mirabegron Market Sales by Geography (USD MN)
  • Botox Market Sales by Geography (USD MN)
  • Neuromodulation Market Sales by Geography (USD MN)
  • Other Market Sales by Geography (USD MN)
  • Global Market Analysis by Disease Type (USD MN)
  • Idiopathic Overactive Bladder Market Sales by Geography (USD MN)
  • Neurogenic Overactive Bladder Market Sales by Geography (USD MN)
  • Global Market Analysis by Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales by Geography (USD MN)
  • Retail Pharmacies Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR112113273

The global demand for Overactive Bladder Treatment Market is presumed to reach the market size of nearly USD 6.54 BN by 2030 from USD 4.33 BN in 2022 with a CAGR of 5.29% under the study period 2023 - 2030.

Overactive bladder (OAB) treatment involves various approaches to managing the symptoms associated with this condition. OAB is characterized by a sudden, involuntary contraction of the muscles in the bladder wall, leading to a frequent and urgent need to urinate. The treatment aims to alleviate symptoms and improve the individual's quality of life.

MARKET DYNAMICS

The Overactive Bladder (OAB) Treatment market is driven by several key factors. A primary contributor is the increasing prevalence of OAB, particularly among the aging population, leading to a rising demand for effective treatment options. Advancements in medical research and pharmaceutical innovation play a crucial role, with the development of targeted medications offering improved efficacy and fewer side effects. The market is further shaped by the growing recognition of behavioral therapies and lifestyle modifications as effective first-line treatments for OAB. This shift towards non-invasive approaches contributes to the expansion of the market for behavioral therapy programs and related interventions. Neuromodulation therapies and surgical interventions for OAB cases resistant to other treatments also influence the market, driven by technological advancements in devices and procedures.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of overactive bladder treatment. The growth and trends of overactive bladder treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the overactive bladder treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

  • Anticholinergics
  • Mirabegron
  • Botox
  • Neuromodulation
  • Other

By Disease Type

  • Idiopathic Overactive Bladder
  • Neurogenic Overactive Bladder

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Overactive Bladder Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Overactive Bladder Treatment market include Pfizer, Inc., AbbVie Inc., Astellas Pharma Inc., Medtronic, Sumitomo Pharma America, Inc.( Urovant Sciences.), Viatris Inc., Teva Pharmaceutical Industries Ltd., Hisamitsu Pharmaceutical Co., Inc, Macleods Pharmaceuticals Ltd., Endo International plc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . OVERACTIVE BLADDER TREATMENT - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Type
    • 3.7.2 Market Attractiveness Analysis By Disease Type
    • 3.7.3 Market Attractiveness Analysis By Distribution Channel
    • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL OVERACTIVE BLADDER TREATMENT MARKET ANALYSIS BY TYPE

  • 5.1 Overview by Type
  • 5.2 Historical and Forecast Data
  • 5.3 Analysis by Type
  • 5.4 Anticholinergics Historic and Forecast Sales by Regions
  • 5.5 Mirabegron Historic and Forecast Sales by Regions
  • 5.6 Botox Historic and Forecast Sales by Regions
  • 5.7 Neuromodulation Historic and Forecast Sales by Regions
  • 5.8 Other Historic and Forecast Sales by Regions

6 . GLOBAL OVERACTIVE BLADDER TREATMENT MARKET ANALYSIS BY DISEASE TYPE

  • 6.1 Overview by Disease Type
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Disease Type
  • 6.4 Idiopathic Overactive Bladder Historic and Forecast Sales by Regions
  • 6.5 Neurogenic Overactive Bladder Historic and Forecast Sales by Regions

7 . GLOBAL OVERACTIVE BLADDER TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 7.1 Overview by Distribution Channel
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Distribution Channel
  • 7.4 Hospital Pharmacies Historic and Forecast Sales by Regions
  • 7.5 Retail Pharmacies Historic and Forecast Sales by Regions
  • 7.6 Others Historic and Forecast Sales by Regions

8 . GLOBAL OVERACTIVE BLADDER TREATMENT MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2. North America By Segment Sales Analysis
    • 8.3.3. North America By Country Sales Analysis
    • 8.3.4. United State Sales Analysis
    • 8.3.5. Canada Sales Analysis
    • 8.3.6. Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2. Europe by Segment Sales Analysis
    • 8.4.3. Europe by Country Sales Analysis
    • 8.4.4. United Kingdom Sales Analysis
    • 8.4.5. France Sales Analysis
    • 8.4.6. Germany Sales Analysis
    • 8.4.7. Italy Sales Analysis
    • 8.4.8. Russia Sales Analysis
    • 8.4.9. Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2. Asia Pacific by Segment Sales Analysis
    • 8.5.3. Asia Pacific by Country Sales Analysis
    • 8.5.4. China Sales Analysis
    • 8.5.5. India Sales Analysis
    • 8.5.6. Japan Sales Analysis
    • 8.5.7. South Korea Sales Analysis
    • 8.5.8. Australia Sales Analysis
    • 8.5.9. South East Asia Sales Analysis
    • 8.5.10. Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2. Latin America by Segment Sales Analysis
    • 8.6.3. Latin America by Country Sales Analysis
    • 8.6.4. Brazil Sales Analysis
    • 8.6.5. Argentina Sales Analysis
    • 8.6.6. Peru Sales Analysis
    • 8.6.7. Chile Sales Analysis
    • 8.6.8. Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2. Middle East & Africa by Segment Sales Analysis
    • 8.7.3. Middle East & Africa by Country Sales Analysis
    • 8.7.4. Saudi Arabia Sales Analysis
    • 8.7.5. UAE Sales Analysis
    • 8.7.6. Israel Sales Analysis
    • 8.7.7. South Africa Sales Analysis
    • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE OVERACTIVE BLADDER TREATMENT COMPANIES

  • 9.1. Overactive Bladder Treatment Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10 . COMPANY PROFILES OF OVERACTIVE BLADDER TREATMENT INDUSTRY

  • 10.1. Company Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. Pfizer Inc.
    • 10.3.1. Company Overview
    • 10.3.2. Company Revenue
    • 10.3.3. Products
    • 10.3.4. Recent Developments
  • 10.4. AbbVie Inc.
    • 10.4.1. Company Overview
    • 10.4.2. Company Revenue
    • 10.4.3. Products
    • 10.4.4. Recent Developments
  • 10.5. Astellas Pharma Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Company Revenue
    • 10.5.3. Products
    • 10.5.4. Recent Developments
  • 10.6. Medtronic
    • 10.6.1. Company Overview
    • 10.6.2. Company Revenue
    • 10.6.3. Products
    • 10.6.4. Recent Developments
  • 10.7. Sumitomo Pharma America Inc.( Urovant Sciences.)
    • 10.7.1. Company Overview
    • 10.7.2. Company Revenue
    • 10.7.3. Products
    • 10.7.4. Recent Developments
  • 10.8. Viatris Inc.
    • 10.8.1. Company Overview
    • 10.8.2. Company Revenue
    • 10.8.3. Products
    • 10.8.4. Recent Developments
  • 10.9. Teva Pharmaceutical Industries Ltd.
    • 10.9.1. Company Overview
    • 10.9.2. Company Revenue
    • 10.9.3. Products
    • 10.9.4. Recent Developments
  • 10.10. Hisamitsu Pharmaceutical Co. Inc
    • 10.10.1. Company Overview
    • 10.10.2. Company Revenue
    • 10.10.3. Products
    • 10.10.4. Recent Developments
  • 10.11. Macleods Pharmaceuticals Ltd.
    • 10.11.1. Company Overview
    • 10.11.2. Company Revenue
    • 10.11.3. Products
    • 10.11.4. Recent Developments
  • 10.12. Endo International plc
    • 10.12.1. Company Overview
    • 10.12.2. Company Revenue
    • 10.12.3. Products
    • 10.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies